Canadian National Breast Screening Study

Last updated

The Canadian National Breast Screening Study, sometimes abbreviated as CNBSS or NBSS, was a randomized trial conducted with the aim of evaluating whether mammography reduced breast cancer incidence or mortality among women who underwent screening. [1] The trial was initiated in 1980, and was conducted in fifteen screening centers in six different Canadian provinces. [1] It was the first study designed to determine whether mammography was effective among women between the ages of 40 and 49. [2]

Contents

Methodology

In the CNBSS, nearly 90,000 women were randomly assigned to either undergo mammographic screening annually, or not undergo it, for five years (1980-1985). [3] [4] The women who participated in the study were aged 40–59, and were divided into two groups: the age 40-49 group and the age 50-59 group. [3] The women aged 40–49 in the mammography group also received annual breast exams, as did the women aged 50–59 in both the mammography and control groups. [3] The women aged 40–49 in the control group received only one breast exam, after which they were told to remain under the care of their family doctor. [1] [3]

Results

The first paper reporting on results of the study was published in 1992, whereupon it generated considerable debate in the scientific community. [4] In February 2014, the BMJ published more results from the study after following up on the participants for twenty-five years, with the authors concluding that "annual mammography in women aged 40-59 does not reduce mortality from breast cancer beyond that of physical examination or usual care when adjuvant therapy for breast cancer is freely available." [1] The study also reported substantial overdiagnosis among women who had been screened, which the authors stated accounted for about 22% of the cancers detected by screening. [1]

Reaction

H. Gilbert Welch, of the Dartmouth Institute for Health Policy and Clinical Practice, has described the CNBSS as “probably the most meticulously done randomized trial of screening mammography." [5] In contrast, in response to the 2014 study reporting on the results of the CNBSS after twenty-five years of follow up, the American College of Radiology (ACR) and Society of Breast Imaging issued a statement describing the paper as “an incredibly misleading analysis based on the deeply flawed and widely discredited Canadian National Breast Screening Study.” [5] The ACR's statement also claimed that the investigators who conducted the CNBSS allocated women with "large incurable cancers" to the mammography group, which led to more women dying in the screened group. [6] Welch responded to this statement by arguing that if it was true, there would have been more deaths among screened women, when in fact there were the same number of deaths among both the screened and unscreened groups. [6] A 2015 review regarding the CNBSS concluded that its findings are "not applicable to current practice" because the study included a high proportion of women with palpable tumors, which, according to the authors of the review, "cannot contribute to an improved mortality reduction." [4]

Related Research Articles

<span class="mw-page-title-main">Breast cancer</span> Cancer that originates in mammary glands

Breast cancer is a cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin.

<span class="mw-page-title-main">Mammography</span> Process of using low-energy X-rays to examine the human breast for diagnosis and screening

Mammography is the process of using low-energy X-rays to examine the human breast for diagnosis and screening. The goal of mammography is the early detection of breast cancer, typically through detection of characteristic masses or microcalcifications.

<span class="mw-page-title-main">Screening (medicine)</span> Brief medical evaluation to detect unnoticed health problems

Screening, in medicine, is a strategy used to look for as-yet-unrecognised conditions or risk markers. This testing can be applied to individuals or to a whole population without symptoms or signs of the disease being screened.

Overdiagnosis is the diagnosis of disease that will never cause symptoms or death during a patient's ordinarily expected lifetime and thus presents no practical threat regardless of being pathologic. Overdiagnosis is a side effect of screening for early forms of disease. Although screening saves lives in some cases, in others it may turn people into patients unnecessarily and may lead to treatments that do no good and perhaps do harm. Given the tremendous variability that is normal in biology, it is inherent that the more one screens, the more incidental findings will generally be found. For a large percentage of them, the most appropriate medical response is to recognize them as something that does not require intervention; but determining which action a particular finding warrants can be very difficult, whether because the differential diagnosis is uncertain or because the risk ratio is uncertain.

Ductal carcinoma <i>in situ</i> Pre-cancerous breast lesion

Ductal carcinoma in situ (DCIS), also known as intraductal carcinoma, is a pre-cancerous or non-invasive cancerous lesion of the breast. DCIS is classified as Stage 0. It rarely produces symptoms or a breast lump that can be felt, typically being detected through screening mammography. It has been diagnosed in a significant percentage of men.

<span class="mw-page-title-main">Philip Strax</span> American physician

Philip Strax was an American radiologist who pioneered the use of mammography to screen for early breast cancer. With his co-investigators, the statistician Sam Shapiro and the surgeon Louis Venet, he conducted a randomized controlled trial comparing outcomes of over 60,000 women who received either mammogram and clinical breast exam or standard medical care. The first results of this study were published in the Journal of the American Medical Association (JAMA) in 1966. The study demonstrated that screening mammograms, which are routine periodic mammograms of asymptomatic women, could find breast cancer at an early enough stage to save lives. For this research Strax and Shapiro shared the Kettering Prize for outstanding contributions to cancer diagnosis or treatment in 1988.

The United States Preventive Services Task Force (USPSTF) is "an independent panel of experts in primary care and prevention that systematically reviews the evidence of effectiveness and develops recommendations for clinical preventive services". The task force, a volunteer panel of primary care clinicians with methodology experience including epidemiology, biostatistics, health services research, decision sciences, and health economics, is funded, staffed, and appointed by the U.S. Department of Health and Human Services' Agency for Healthcare Research and Quality.

<span class="mw-page-title-main">Breast cancer screening</span> Medical screening of asymptomatic, healthy women for breast cancer

Breast cancer screening is the medical screening of asymptomatic, apparently healthy women for breast cancer in an attempt to achieve an earlier diagnosis. The assumption is that early detection will improve outcomes. A number of screening tests have been employed, including clinical and self breast exams, mammography, genetic screening, ultrasound, and magnetic resonance imaging.

<span class="mw-page-title-main">Molecular breast imaging</span>

Molecular breast imaging (MBI), also known as scintimammography, is a type of breast imaging test that is used to detect cancer cells in breast tissue of individuals who have had abnormal mammograms, especially for those who have dense breast tissue, post-operative scar tissue or breast implants.

Daniel B. Kopans, MD, FACR is a radiologist specializing in mammography and other forms of breast imaging.

<span class="mw-page-title-main">Cancer screening</span> Method to detect cancer

The objective of cancer screening is to detect cancer before symptoms appear, involving various methods such as blood tests, urine tests, DNA tests, and medical imaging. The purpose of screening is early cancer detection, to make the cancer easier to treat and extending life expectancy. In 2019, cancer was the second leading cause of death globally; more recent data is pending due to the COVID-19 pandemic.

Thomas M. Kolb is an American radiologist specializing in the detection and diagnosis of breast cancer in young, predominantly high-risk premenopausal women. He has served as an assistant clinical professor of Radiology at Columbia University College of Physicians and Surgeons from 1994–2010. Kolb is double board certified, having received his training in pediatrics at the Albert Einstein College of Medicine in Bronx, New York, and in diagnostic radiology at the Columbia-Presbyterian Medical Center in New York.

Overscreening, also called unnecessary screening, is the performance of medical screening without a medical indication to do so. Screening is a medical test in a healthy person who is showing no symptoms of a disease and is intended to detect a disease so that a person may prepare to respond to it. Screening is indicated in people who have some threshold risk for getting a disease, but is not indicated in people who are unlikely to develop a disease. Overscreening is a type of unnecessary health care.

<span class="mw-page-title-main">H. Gilbert Welch</span> American doctor

H. Gilbert Welch is an American academic physician and cancer researcher. He was an internist at the Veterans Administration Medical Center in White River Junction, Vermont, as well as a professor of medicine at the Dartmouth Institute for Health Policy and Clinical Practice. In September 2018, Welch resigned from Dartmouth College after a 20-month long research misconduct investigation at Dartmouth concluded he had committed plagiarism.

<span class="mw-page-title-main">Breast imaging</span>

In medicine, breast imaging is a sub-speciality of diagnostic radiology that involves imaging of the breasts for screening or diagnostic purposes. There are various methods of breast imaging using a variety of technologies as described in detail below. Traditional screening and diagnostic mammography uses x-ray technology and has been the mainstay of breast imaging for many decades. Breast tomosynthesis is a relatively new digital x-ray mammography technique that produces multiple image slices of the breast similar to, but distinct from, computed tomography (CT). Xeromammography and galactography are somewhat outdated technologies that also use x-ray technology and are now used infrequently in the detection of breast cancer. Breast ultrasound is another technology employed in diagnosis and screening that can help differentiate between fluid filled and solid lesions, an important factor to determine if a lesion may be cancerous. Breast MRI is a technology typically reserved for high-risk patients and patients recently diagnosed with breast cancer. Lastly, scintimammography is used in a subgroup of patients who have abnormal mammograms or whose screening is not reliable on the basis of using traditional mammography or ultrasound.

Marjorie Clare Dalgarno (1901–1983) was an Australian radiologist and a pioneer of mammography. She performed the first mammogram in Australia at the Rachel Forster Hospital and demonstrated the benefits of mammography as a breast cancer screening tool.

Etta Driscoll Pisano is an American breast imaging researcher. She is a professor in residence of radiology at the Beth Israel Deaconess Medical Center and chief research dean at the American College of Radiology. In 2008, she was elected a member of the National Academy of Medicine.

Dense breast tissue, also known as dense breasts, is a condition of the breasts where a higher proportion of the breasts are made up of glandular tissue and fibrous tissue than fatty tissue. Around 40–50% of women have dense breast tissue and one of the main medical components of the condition is that mammograms are unable to differentiate tumorous tissue from the surrounding dense tissue. This increases the risk of late diagnosis of breast cancer in women with dense breast tissue. Additionally, women with such tissue have a higher likelihood of developing breast cancer in general, though the reasons for this are poorly understood.

Paula Gordon is a Canadian radiologist and medical researcher specializing in breast cancer. She is a Clinical Professor in the Department of Radiology at the University of British Columbia.

<span class="mw-page-title-main">Rachel Brem</span> American radiologist and physician

Rachel F. Brem is an American diagnostic radiologist, professor of radiology at the George Washington University School of Medicine & Health Sciences, and director of the Breast Imaging and Interventional Center at George Washington University’s Cancer Center. She previously served as director of Breast Imaging at Johns Hopkins. Brem develops novel technologies to better support early diagnosis and treatment of breast cancer. She is a fellow of the American College of Radiology and the Society of Breast Imaging.

References

  1. 1 2 3 4 5 Miller, AB; Wall, C; Baines, CJ; Sun, P; To, T; Narod, SA (11 February 2014). "Twenty five year follow-up for breast cancer incidence and mortality of the Canadian National Breast Screening Study: randomised screening trial". BMJ (Clinical Research Ed.). 348: g366. doi:10.1136/bmj.g366. PMC   3921437 . PMID   24519768.
  2. ↑ Burhenne, LJ; Burhenne, HJ (October 1993). "The Canadian National Breast Screening Study: a Canadian critique". AJR. American Journal of Roentgenology. 161 (4): 761–3. doi: 10.2214/ajr.161.4.8372753 . PMID   8372753.
  3. 1 2 3 4 Simon, Stacy (12 February 2014). "Canadian Study Questions Mammogram Screening; Findings Unlike Those of Other Studies". American Cancer Society. Retrieved 2 September 2015.
  4. 1 2 3 Heywang-Köbrunner, S. H.; Schreer, I.; Hacker, A.; Noftz, M. R.; Katalinic, A. (28 May 2015). "Conclusions for mammography screening after 25-year follow-up of the Canadian National Breast Cancer Screening Study (CNBSS)". European Radiology. 26 (2): 342–350. doi:10.1007/s00330-015-3849-2. PMC   4712234 . PMID   26017741.
  5. 1 2 Branswell, Helen (12 February 2014). "Contentious Canadian study says mammography doesn't cut deaths from breast cancer". National Post. Retrieved 2 September 2015.
  6. 1 2 Kaplan, Karen (19 February 2014). "Cancer screening expert to radiologists: Stop lying about mammograms". Los Angeles Times. Retrieved 2 September 2015.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.